Association of multiple myeloma and gastric adenocarcinoma

Multipl mieloma ve mide adenokanseri birlikteliği

Cengiz Demir1, Murat Atmaca2, Eyup Tasdemir1, Servet Efe1

1Department of Hematology and 2Internal Medicine, Faculty of Medicine, Yuzuncu Yil University, Van, Türkiye

ABSTRACT

Solid tumors associated with multiple myeloma have been demonstrated. However, it is a controversial subject whether there is a risk factor for the development of a secondary tumor. Here we reported a case with multiple myeloma and gastric adenocarcinoma. A 77 years old male patient was admitted with complaints of bone pain, left leg weakness, weight loss and epigastric pain. Patient's examination revealed monoclonal gammopathy, lytic bone lesions and infiltration of plasma cells in bone marrow. Endoscopic examination revealed a mass in the proximal stomach and pathological examination of ulcerated mass showed gastric adenocarcinoma.

Coexistence of these two disease entities needed to be explained by further large-scale researches.

Key Words: Multiple myeloma, gastric adenocarcinoma, coexistence

INTRODUCTION

Multiple myeloma presents with osteolytic bone lesions, which may co-exist with renal and bone marrow failure, hypercalcemia and monoclonal gammopathy, are considered to be a neoplastic disorder of monoclonal plasma cells.1 Multiple myeloma constitutes an approximately %1 of malign diseases and %10 of hematologic malignancies. The co-existence of solid tumors with multiple myeloma has already been shown in literature; however for the development of secondary solid tumors, multiple myeloma should be brought under scrutiny and discussion about whether it is a risk factor or not.2,3,4 Disordered immunity and procedures such as chemotherapy and radiotherapy which are performed in multiple myeloma may contribute to the development of secondary cancers.5 The co-existence of multiple neoplasia in a patient is not considered to be common, and thus multiple neoplasia were reported to be around %1.2 and %4.5 based on clinical studies and autopsy series.6 If the diagnostic ranges of different malignancies are shorter than six months, they are called synchronized; and if they are longer than six months, they are called metachronized neoplasms. In this study, a case diagnosed with synchronized multiple myeloma and gastric adenocarcinoma was presented.
CASE

A 77-year-old male patient referred to our clinic with complaints of bone pains, fatigue in left leg, weight loss and epigastric pains. He had a medical history of epigastric complaints lasting for six months, and lost fifteen kilograms of weight within this period. Since no improvement had been observed in the complaints of the patient who was using proton pump inhibitors for his epigastric complaints and since he experienced an abrupt onset of fatigue and numbness in his left leg, he was admitted in our clinic for further investigation.

There was no disease history both in his and his family. In the physical examination the patient was cooperated. Cardiac and pulmonary examinations revealed normal. The blood pressure was measured as 130/70 mmHg and pulse as 76/min. In the bottom examination, there was sensitivity in epigastrium region, being understood in palpation. In the neurologic examination, motor tissue force was 4/5 in upper extremities and 3/5 in the lower left extremity; there was also hypoesthesia. The motor force in the right lower extremity was normal. Laboratory analyses are shown in (Table 1).

Table 1. Laboratory findings of the patient

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hb (gr/dl)</td>
<td>13.2</td>
</tr>
<tr>
<td>MCV (fl)</td>
<td>83</td>
</tr>
<tr>
<td>RBC (10^6/µL)</td>
<td>4.8</td>
</tr>
<tr>
<td>WBC (10^3/µL)</td>
<td>4.200</td>
</tr>
<tr>
<td>PLT (10^3/µL)</td>
<td>492.000</td>
</tr>
<tr>
<td>ESR (sec)</td>
<td>72</td>
</tr>
</tbody>
</table>

High levels of globulin and sedimentation suggested multiple myeloma. Monoclonal gammopathy was observed in protein electrophoresis. Immunoglobulin levels were found as thus: IgG 55.8 g/L, IgA 0.66 g/L, IgM 0.23 g/L. Bone marrow biopsy was performed; and the plasma cell proportion in bone marrow was 45% (Figure 1-2). In the direct encephalography, there were lytic lesions. In the thoracolomber computerized tomography, there was a remarkable height loss in T10 vertebra corpus and a compression fracture in the anterior. There were soft tissue entities involving vertebra corpus in T9-11 and the posterior elements and protruding to anterior and posterior subarachnoid distance and remarkably constricting the spinal channel (Figure 3).

This patient who was diagnosed to have multiple myeloma underwent VAD (Vincristine, Adriablastina, Dexamethasone) chemotherapy. For the involved vertebra, a total of 4500 cGy radiotherapy in a daily dose of 180 cGy and 25 fractions was initiated. After one week of the initiation of the treatment, upper gastrointestinal system endoscopy was conducted on the patient, since the still had chronic epigastric complaints. In this examination, partially swollen and disorganized areas in ulcerated mucosa in cardia proximal under cardio esophageal sphincter. In the pathologic examination of the biopsies taken from these areas a diagnosis of adenocarcinoma was made (Figure 4).

Lymphadenopathy was detected in the mediassten and both of the axillaries regions in the examinations of thorax computerized tomography (the greatest lymphadenopathy was in a measure of 1.4 cm). In the computerized tomography, minimal liquid was observed in pelvic and around the liver. There was also a thickening of wall in gastro esophageal junction. The patient died after a cardio-pulmonary arrest on fifteenth day of his hospitalization. Pulmonary embolus was thought to be the possible cause of his death.

DISCUSSION

The co-existence of multiple neoplasies in a patient is a rarely observed condition. Multiple neoplasia may be in synchronized or metachronized form. The reason of the co-existence of multiple neoplasia may be the exposure of multiple organs to carcinogenic agents, the increased susceptibility of individuals with multiple genetic anomalies to cancer (p53 gene mutations and the other gene defects responsible for DNA restoration). Another reason may be the carcinogenic affect of therapeutic agents used for the first primary cancer treatment.7-11

The impaired immune system and the chemoradiotherapy applied for myeloma treatment are considered to be risk factors in the development of secondary cancers.5 However, a synchronic diagnosis of malignancies in our patient brought to the mind that another inducing factor. In recent years, publications reported the frequency of the secondary primary cancers.7

In a study conducted by Stegeman at al. multiple myeloma and solid tumor co-existence was found to be 3%.3 In 2003 Kyle at al. reported that, in 1027 patients diagnosed with multiple myeloma, the proportion of secondary hematologic malignity was %0.7 and the proportion secondary solid malignity was %1.9.12 There are also case presenta-
tions focusing on the co-existence of gastric cancer and multiple myeloma in Japan, which has a higher prevalence of gastric cancers. Tuncer at al. reported in a epidemiological study that upper gastrointestinal system cancers in our region had a higher prevalence compared to the western regions of Turkey. Based on the above premises, it would be much more tempting to say that further investigations would be imperative in order to have an adequate understanding of whether the co-existence of these two diseases is only accidental or whether there is any cause and effect relationship between these two diseases especially in regions in which the prevalence of gastric cancers are higher.

In our presented case, treatment for multiple myeloma was thought to be preliminary due to the fact that neurologic deficits came to the fore. Gastric adenocarcinoma had been accepted as a localized disease by the general surgery and curative treatment had been recommended. However, the patient and his relative had not given consent. Therefore, only chemo-radiotherapy for multiple myeloma could be applied. In a study conducted by Sang et al. in 2004, and carried out on three cases synchronically diagnosed to have solid tumors and multiple myeloma, the treatment was directed towards solid tumors since the prognosis was bad. The three cases manifested multiple myeloma as smoldering or stage 1. The response taken from the treatment initiated for these patients was similar to the response taken from the cases that had no multiple myeloma.

In conclusion, further studies based on larger series of patients should be conducted in order to understand whether there is any parallel between the etiologies of these two diseases or any inducing factors underlying behind these two rare and co-existent conditions.

REFERENCES


